The cytosolic protein Mig6 (the product of mitogen-inducible gene 6, now formally designated ERRFI1) is a feedback inhibitor of EGFR and other ErbB-family members [1] [2] [3] [4] . Mig6 expression is induced by EGFR signaling via the Ras MAP kinase pathway 5 as well as by other mitogenic and stress stimuli 6 . Mig6 directly binds to EGFR and inhibits its signaling both by inhibiting the catalytic activity [7] [8] [9] and by directing the internalization and degradation of the kinase 10, 11 . Deletion of the Mig6-encoding gene in mice has been shown to hyperactivate EGFR signaling, thus leading to skin hyperplasia and spontaneous tumor formation in skin, lung and other tissues 12, 13 . A recent study has shown that loss of Mig6 promotes tumor initiation and progression in a mouse model of mutant EGFR-driven lung adenocarcinoma 14 . In humans, Mig6 expression is diminished in a number of tumors 12, 15 , and the ERFFI1 chromosomal locus (1p36) is a frequent site of deletion in multiple tumor types 6 .
a r t i c l e s
The cytosolic protein Mig6 (the product of mitogen-inducible gene 6, now formally designated ERRFI1) is a feedback inhibitor of EGFR and other ErbB-family members [1] [2] [3] [4] . Mig6 expression is induced by EGFR signaling via the Ras MAP kinase pathway 5 as well as by other mitogenic and stress stimuli 6 . Mig6 directly binds to EGFR and inhibits its signaling both by inhibiting the catalytic activity [7] [8] [9] and by directing the internalization and degradation of the kinase 10, 11 . Deletion of the Mig6-encoding gene in mice has been shown to hyperactivate EGFR signaling, thus leading to skin hyperplasia and spontaneous tumor formation in skin, lung and other tissues 12, 13 . A recent study has shown that loss of Mig6 promotes tumor initiation and progression in a mouse model of mutant EGFR-driven lung adenocarcinoma 14 . In humans, Mig6 expression is diminished in a number of tumors 12, 15 , and the ERFFI1 chromosomal locus (1p36) is a frequent site of deletion in multiple tumor types 6 .
The domain structure of Mig6 includes an N-terminal CRIB domain, a motif that mediates association with the Rho-family GTPase Cdc42 (ref. 16) , and a more C-terminal ErbB-binding region, which is necessary and sufficient for binding and inhibition of EGFR 7, 8, 17 . Functional dissection of this region has identified a fragment that binds EGFR (Mig6 residues 336-364, termed segment 1) but lacks full inhibitory activity 8, 18 . Inclusion of ~50 additional residues (segment 2, residues 365-412) is required for potent inhibition of EGFR in vitro and in cells. Partly on the basis of a crystal structure of Mig6 segment 1 in complex with EGFR, Mig6 has been proposed to inhibit EGFR in an allosteric manner by blocking formation of the activating receptor dimer 8 . No structural information is available for Mig6 segment 2, and how it contributes to inhibition is not understood at a mechanistic level. Furthermore, a particularly interesting and crucial aspect of Mig6 function-its ability to specifically target the activated form of the receptor-remains unexplained 1, 2, 17 .
EGFR is a key regulator of cellular proliferation, migration and survival, and it is among the most frequently altered proteins in human cancers, particularly glioblastoma and lung adenocarcinoma [19] [20] [21] [22] . In non-small cell lung cancer, common oncogenic alterations in the EGFR kinase domain include the L858R point mutation, deletions within exon 19 (Ex19Del) and insertions in the region encoded by exon 20 (Ex20Ins) 23 . Patients with lung cancer whose tumors are driven by some of these mutations have been shown to respond well to EGFR kinase inhibitors including gefitinib, erlotinib and afatinib 24, 25 , but secondary resistance mechanisms have limited the long-term efficacy of these treatments 26 . Genomic alterations in the extracellular, C-terminal and catalytic regions of EGFR have been identified in glioblastoma, and EGFR amplifications are a hallmark of the classic subtype of this disease 21, [27] [28] [29] [30] . However, EGFR inhibitors have not yielded dramatic results in glioblastoma treatment to date.
A recent investigation of the substrate specificity of EGFR with an in vitro peptide-library approach has revealed that EGFR preferentially a r t i c l e s phosphorylates substrates that are already phosphorylated on a tyrosine residue in the P+1 position (M.J.E., C. Yun, M. Begley and L. Cantley, unpublished data). Phosphorylation of such 'primed' sites will therefore lead to doubly phosphorylated 'pYpY' elements in cognate substrates. Interestingly, Mig6 can be phosphorylated on two adjacent tyrosine residues (Y394 and Y395) in an EGFR-or an ErbB2-dependent manner 14, 31, 32 . This site lies in the crucial segment 2 region of Mig6, but the functional consequences of phosphorylation of these residues have not been clearly elucidated. Very recently, phosphorylation of Y394 has been reported to promote increased binding of Mig6 to the receptor 14 and to diminish the ability of Mig6 to inhibit EGFR 33 .
We set out to elucidate the role of this dual phosphorylation site in Mig6 function at a structural and mechanistic level. We found that Y394-phosphorylated Mig6 directly inhibits EGFR in a peptide substrate-competitive manner. Y394 is phosphorylated by EGFR itself, and this phosphorylation underlies the selectivity of Mig6 for activated receptors. Y394 phosphorylation is dramatically accelerated by prior phosphorylation of Y395, a site that is preferentially phosphorylated by Src. Small-molecule inhibition and short hairpin RNA (shRNA)-mediated knockdown of Src diminished levels of Mig6 phosphorylation at this site, and Y395F-mutant Mig6 is impaired in its ability to inhibit transformation by oncogenic EGFR mutants. Crystal structures explain the priming effect of Y395 phosphorylation and show that once phosphorylated on Y394, segment 2 rearranges to form a hairpin-like element that blocks the peptide substrate-binding cleft. Segment 1 binds the EGFR C lobe, anchoring segment 2 and rendering it an effective substrate-competitive inhibitor. Collectively, our results indicate that Mig6 is an activity-based inhibitor of EGFR; it exploits the phosphotransfer activity of a target receptor molecule to inactivate it. This negative feedback mechanism is subverted in human tumors: we found that the Mig6 gene ERRFI1 is frequently deleted in EGFR-amplified gliomablastomas.
RESULTS

Mig6 is phosphorylated on Y394 and Y395 by activated EGFR
Using quantitative tandem mass spectrometry 34 , we analyzed the phosphoproteome of NIH-3T3 cells stably expressing wild-type (WT) or oncogenic mutant EGFR ( Supplementary Fig. 1 and Supplementary  Table 1 ). To complement previous phosphoproteomic studies that focused on the L858R and Ex19Del EGFR mutants 14, 31, 35 , we analyzed an exon-20 insertion mutant (insNPG) and an oncogenic C-terminal deletion mutant (CTDel1, which lacks residues 1010-1152) [36] [37] [38] . We included a kinase-dead (D837A) version of the exon-20 insertion mutant as a negative control. We found that more than 500 proteins were hyperphosphorylated in EGFR-mutant cells, and we identified a doubly phosphorylated (p) Mig6 pY394pY395 peptide (Fig. 1a) .
To further explore the genesis and functional consequences of Mig6 phosphorylation of Y394 and Y395, we raised a phosphospecific antibody against the dual pY394pY395 site (Supplementary Fig. 2a,b) . Immunoblotting with this anti-pMig6 antibody revealed constitutive phosphorylation at this site in NIH-3T3 cells stably expressing mutant EGFR and revealed EGF-induced phosphorylation in cells expressing WT EGFR (Fig. 1b) . In addition, we found that endogenous Mig6 was constitutively phosphorylated in PC9 and HCC827 lung cancer cell lines, which contain EGFR Ex19Del mutations (Fig. 1c, lanes 1 and 3) . This Mig6 phosphorylation was abolished by treatment with the EGFR inhibitor erlotinib (Fig. 1c, lanes 2 and 4) , thus suggesting that active EGFR is responsible for phosphorylation of Mig6.
EGFR phosphorylates Y394 primed by Y395 phosphorylation
We next examined the ability of EGFR to directly phosphorylate ten-residue synthetic peptides spanning this site (residues 390-399) that were either unphosphorylated (YY) or already phosphorylated at either Y394 or Y395 (designated pYY and YpY, respectively). The purified kinase domains of both WT EGFR and the L858R mutant were able to phosphorylate the YY peptide, but the rate of phosphorylation of the YpY peptide was dramatically faster (Fig. 2a) . This priming effect was specific for the P+1 phosphorylation in the YpY sequence because the rate of phosphorylation of the pYY peptide was similar to that of the unphosphorylated YY species. Using quantitative mass spectrometry, we further studied EGFR phosphorylation of the YY peptide to determine whether either or both Y394 and Y395 are phosphorylated (Fig. 2b) . The major product of the reaction was pYY, the Y394-phosphorylated species, but the YpY and pYpY species were also produced at lower levels. We also observed preferential phosphorylation of Y394 by EGFR when the substrate was a longer Mig6 fragment encompassing both segments 1 and 2 (segment 1+2, residues 330-399; Supplementary Fig. 2c,d) .
Although EGFR can phosphorylate Y394 in the absence of prior phosphorylation of Y395, the results above suggest that phosphorylation of Y394 could be primed by prior phosphorylation of Y395 by a npg a r t i c l e s the functional effect of phosphorylation at these sites. Expression of ligand-activated WT or oncogenic-mutant EGFR transformed NIH-3T3 cells, but this transformation was completely blocked by coexpression of WT Mig6, as assessed by soft agar colony formation ( Fig. 3a-c) . By contrast, Y394F-and Y394F Y395F-mutant Mig6 proteins were markedly impaired in their ability to inhibit EGFRdriven transformation ( Fig. 3a-c) . The Y395F mutant was also modestly impaired. WT Mig6 effectively blocked EGF-induced phosphorylation of the WT receptor in these cells, but Y394F Y395F-mutant Mig6 did not (Fig. 3d) . A similar effect was apparent in cells expressing mutant EGFR ( Supplementary Fig. 3a,b) . Further, we probed binding of Mig6 to EGFR in coimmunoprecipitation experiments with cell lysates prepared from HEK-293T cells coexpressing WT or mutant Mig6 with L858R EGFR. Although we observed WT Mig6 in complex with L858R EGFR (Fig. 3e, lane 1) , coprecipitation of Mig6 with L858R EGFR was markedly diminished by mutation of these phosphorylation sites (Fig. 3e , lanes 2 and 4) and by erlotinib treatment (Supplementary Fig. 3c ). Together, these results indicate that the Y394-Y395 phosphorylation site in Mig6 is critical for its ability to effectively bind and inhibit both WT and mutant EGFR and to block cellular transformation driven by activated EGFR. We examined the role of c-Src in Mig6 phosphorylation and subsequent binding and inhibition of EGFR, using both pharmacologic and shRNA approaches to silence c-Src activity. Treatment of NIH-3T3 cells stably coexpressing WT EGFR and Mig6 with the Src inhibitor dasatinib attenuated EGF-induced phosphorylation of Mig6 on Y394-Y395 (Fig. 3f,g ). Dasatinib treatment also decreased coimmunoprecipitation of EGFR with Mig6 (Fig. 3f) . At 0.5 µM, dasatinib effectively blocked c-Src activation-loop autophosphorylation (at Y416) and decreased Mig6 phosphorylation in a dose-dependent manner (Fig. 3f, lane 8) . We also noted increased EGF-induced phosphorylation of EGFR at increasing concentrations of dasatinib (Fig. 3f, lanes 2, 4, 6 and 8) , a result consistent with diminished Mig6-mediated receptor inhibition. Src also modulated Mig6 phosphorylation and function in lung cancer cell lines PC9 and A549, which are driven by mutations in EGFR and KRAS, respectively. We generated PC9 and A549 cells with stable knockdown of c-Src kinase by expressing shRNA targeting c-Src via lentiviral infection and found that EGF-induced phosphorylation of Mig6 at Y394-Y395 was reduced in PC9 cells and was not detectable in A549 cells after Src knockdown (Fig. 3h) .
Y394 phosphorylation underlies activity-based EGFR inhibition
We tested the ability of a segment 1+2 fragment of Mig6, either WT (Mig6-YY) or with phenylalanine substitutions in Y394 and Y395 (Mig6-FY, YF and FF) to inhibit purified EGFR kinase. Whereas the Mig6-YY and Mig6-YF mutants potently inhibited the kinase, the FY and FF mutants had little activity (Fig. 4a) . To specifically determine whether phosphorylation of these residues is required for EGFR inhibition, we prepared semisynthetic Mig6 segment 1+2 proteins in defined phosphorylation states by using intein-mediated expressed protein ligation 41 (Supplementary Fig. 4a,b) and examined the time course of their inhibition of EGFR. All four Mig6 phosphorylation variants were similar in their potency at steady state (YY, pYY, YpY and pYpY; Supplementary Fig. 4c,d ), and they also potently inhibited the intact ligand-bound EGF receptor (Supplementary Fig. 4e ). However, inhibition of EGFR kinase by the YY variant was strongly time dependent (Fig. 4b,c) . Its potency increased by two orders of magnitude during the course of the reaction with WT EGFR, from ~1 µM at the initial time point to 10-20 nM after 20 min. By contrast, Mig6-pYY and Mig6-pYpY exhibited 10-20 nM potency from the earliest time points. We observed a modest but reproducible time-dependent increase in the potency of the Mig6-YpY protein and a more rapid plateau (~12.5 min), results consistent with more rapid phosphorylation of Y394 when Y395 is already phosphorylated. These findings clearly indicate that Mig6 requires a r t i c l e s phosphorylation of Y394 in order to inhibit EGFR; i.e., Mig6-pYY and Mig6-pYpY are the actual inhibitory species.
To directly examine whether phosphorylation of Y394 is associated with EGFR binding and inhibition, we combined the EGFR kinase domain with an approximate two-fold excess of Mig6-YY under reaction conditions for 20 min and separated the products by size-exclusion chromatography (Fig. 4d) . Strikingly, all of the Mig6 that coeluted with EGFR was phosphorylated, as judged by a shift in electrophoretic mobility of the phosphorylated species and by immunoblotting with the phospho-Mig6-specific antibody, whereas little if any of the free Mig6 was phosphorylated.
The lack of phosphorylation of excess Mig6 in this experiment suggested that Mig6 might function as an 'activity-based' inhibitor of EGFR; i.e., once phosphorylated on Y394, it could remain bound to inhibit the same EGFR molecule that catalyzed its phosphorylation. This is a defining property of small-molecule 'mechanism-based' inhibitors, which have exquisite selectivity for their intended target because no free pool of active inhibitor is created 42 . To test this notion, we coexpressed active Myctagged EGFR (L858R) and kinase-dead hemagglutinin (HA)-tagged EGFR (L858R D837N) along with WT Mig6 in HEK-293T cells and examined the levels of Mig6 bound to the L858R and L858R D837N mutants by coimmunoprecipitation. Levels of expression of the two EGFR mutants were similar, but virtually all of the Mig6 coprecipitated with the catalytically active L858R EGFR (Fig. 4e) , although the kinase-dead mutant retained the ability to bind phosphorylated Mig6 (Supplementary Fig. 5a ). Measurement of the rate of dissociation of phosphorylated Mig6 from EGFR in vitro revealed a half-life of ~45 min for the complex (Supplementary Fig. 5b) , which is long in comparison to the 5-10 min required for internalization of activated EGFR in cells 10, 43 . We conclude that Mig6 requires phosphorylation of Y394 for potent inhibition of EGFR. EGFR carries out this phosphorylation, and the rate of dissociation of phosphorylated Mig6 is sufficiently slow that it allows Mig6 to function as an activity-based inhibitor of the receptor.
Structural snapshots of Mig6 inhibition of EGFR
To see how Mig6 inhibits EGFR, we determined three crystal structures of Mig6 fragments bound to EGFR, representing distinct steps in the course of Mig6 inhibition (Table 1 and Fig. 5) . Structures of the kinase in complex with ten-residue Mig6-YpY and Mig6-pYpY peptides explain the priming effect of Y395 phosphorylation (Fig. 5a,b) . In the Mig6-YpY structure, the kinase adopts an active conformation, and the Mig6 peptide interacts with the activation loop in an antiparallel manner, as seen in other kinases in complex with peptide substrates 44 . Y394 is in the phosphoacceptor position, and the backbone amide and carbonyl groups of pY395 (in the P+1 position) hydrogen-bond with the backbone groups of Val876 in the EGFR activation loop (Fig. 5d) . The side chain of pY395 extends across A920, and its phosphate group is positioned to hydrogenbond with K879 and with the backbone amide of A920. These interactions in the P+1 'priming pocket' explain the enhanced phosphorylation of the pY395-phosphorylated Mig6 peptide.
Interestingly, we observed a closely similar mode of binding with the doubly phosphorylated Mig6-pYpY peptide (Fig. 5b,e) . The side chain of pY394 is positioned in the phosphoacceptor site even though it is phosphorylated (Supplementary Fig. 6a) , and pY395 is again observed in the P+1 priming pocket. As explained below, the structure of a longer fragment of phospho-Mig6 bound to EGFR reveals that segment 2 rearranges after phosphorylation of Y394, thus leading us to conclude that this Mig6-pYpY peptide complex represents a transient intermediate in phosphorylation-dependent inhibition.
The structure of the complete, doubly phosphorylated EGFRbinding region of Mig6 (residues 330-399) in complex with EGFR reveals that segment 1 binds across the base of the C lobe as previously described 8 , and segment 2 forms a β-hairpin-like element that occupies the peptide-substrate binding site (Fig. 5c) . Phosphorylated Y394 and Y395 occupy the peptide-substrate site, but the register of the polypeptide chain shifts by one residue in this structure compared with the structures above, such that pY394 occupies the P+1 priming position, and H393 occupies the phosphoacceptor pocket (Fig. 5f) . Likewise, pY395 shifts into the P+2 position. The more N-terminal portion of segment 2 folds back to hydrogen-bond with the pY394-pY395 region to create the β-hairpin-like structure. The phosphate groups of both phosphotyrosine residues make favorable electrostatic interactions: pY395 with K875 in EGFR and pY394 with K879 in EGFR ( Fig. 5f and Supplementary Fig. 6b) . The kinase exhibits inactive features in this structure; the DFG motif is flipped, and the C helix is displaced into an outward, inactive position. These deviations from the stereotypical active conformation appear unrelated to binding of Mig6, and we expect that Mig6 could bind to the kinase in its fully active conformation in a similar manner. 
npg a r t i c l e s
In agreement with the structure, kinetic studies confirm that Mig6 inhibits EGFR in a peptide substrate-competitive manner with an inhibition constant (K i ) of 15.85 nM ( Supplementary  Fig. 7a,b) . A V948R substitution in the Mig6 segment 1-binding site on EGFR decreases the potency of inhibition in vitro by Mig6 segment 1+2 ( Supplementary Fig. 7c) ; this result indicates that interactions of segment 1 are also important for potent inhibition. We propose that segment 1 effectively anchors segment 2 to the kinase, thus rendering it an effective substrate-competitive inhibitor once it is phosphorylated.
ERRFI1 is focally deleted in EGFR-amplified glioblastoma
The Mig6-encoding gene ERRFI was previously noted as one of two genes in a minimal common region of deletion across 18 glioblastoma tumors and 20 cell lines 11 . To better understand Mig6 loss in glioblastoma and lowergrade gliomas, we analyzed 1,057 gliomas characterized by The Cancer Genome Atlas (TCGA) project 21 . ERRFI1, which resides on chromosome 1p36, is in the third most significantly deleted region across all 1,057 tumors, after the well-known tumor suppressors CDKN2A, CDKNB and PTEN (Fig. 6a,b) . In a separate analysis of the 571 glioblastomas in this data set, we found that ERRFI1 is the only gene in the 'peak region' for which deletions in different samples overlap frequently (Fig. 6c) . Deletions of ERRFI1 are primarily In f, Mig6 residues 378-380 form a short β-strand that hydrogen-bonds with residues 395-397 of Mig6 (additional data in Supplementary Fig. 7 ).
a r t i c l e s hemizygous and are present in 24% of glioblastomas, of which 21% are focal events that encompass less than half of chromosome 1p. ERRFI1 is also deleted in 42% of 486 lower-grade gliomas characterized by TCGA, but of these, 37% are large deletions that encompass most of chromosome 1p and occur primarily in oligodendrogliomas with mutations of FUBP1, a known tumor suppressor in these gliomas, which resides on 1p31 (ref. 45) . Interestingly, ERRFI1 deletions were highly correlated with coexisting focal amplifications of EGFR. Across all 1,057 TCGA gliomas in our analysis, 27% of tumors with focal amplification of EGFR also exhibited focal deletions of ERRFI1, compared to 8% of the tumors without EGFR amplification (Fig. 6c) . This is a significant association (one-sided P = 0.00014), even after controlling for lineage and for variations in overall levels of genomic disruption in these samples 46 .
DISCUSSION
Our studies reveal a heretofore-unappreciated mechanism of specificity in Mig6-mediated inhibition; the Mig6 protein is impotent until it is phosphorylated at Y394 by EGFR, and once phosphorylated, Mig6 remains bound to inhibit the receptor that catalyzed its phosphorylation, probably until internalization and degradation of the receptor (Fig. 7a) . This mechanism allows Mig6 to selectively target active receptor molecules. To our knowledge, activity-based inhibition has not been previously described as part of an endogenous regulatory circuit. The bipartite structure of the Mig6 inhibitory element is well suited to this purpose. The Y394-Y395 phosphorylation site in segment 2 detects active EGFR molecules and rearranges to directly inhibit the kinase by occupying the peptide substrate-binding site. This rearrangement presumably requires local dissociation of segment 2, but binding of segment 1 is structurally independent of binding of segment 2, thus allowing segment 1 to anchor Mig6 to an active receptor in the course of phosphorylation and also allowing subsequent rearrangement into the high-affinity complex observed here. Phosphorylation of the Y394-Y395 site would also stabilize the interaction of segment 1 with the kinase C lobe, preventing a Mig6-bound receiver subunit from subsequently acting in an activator role by blocking the asymmetric dimer interface 8 . Although we have not explicitly examined the effect of Y394 phosphorylation of EGFR internalization and degradation, we reason that it must also control these events because they require stable association of Mig6 with the active receptor.
In conflict with our findings, a prior biochemical study found that Y394 phosphorylation diminishes the ability of Mig6 to inhibit EGFR 33 . This conclusion was based on an experiment using semisynthetic Mig6-pY394 to inhibit nearly full-length ligand-bound EGFR (tEGFR). The discrepancy is unlikely to be a result of differences in the EGFR constructs or kinase assays used, because our phosphorylated Mig6 segment 1+2 preparations potently inhibited tEGFR under the conditions used in the earlier study (Supplementary Fig. 4e) . The Mig6 construct used in the earlier study introduced three substitutions near pY394 (S390P, S391G and T392C). In particular, mutation of Thr392 may have affected EGFR inhibition, because this residue contacts the kinase and also hydrogen-bonds with His393, the Mig6 residue that occupies the phosphoacceptor site in the inhibited complex (Fig. 5f) .
We further found that Mig6 inhibition of EGFR is modulated by Src via phosphorylation of Mig6 on Y395. Prior phosphorylation of Y395 dramatically increased the rate of EGFR phosphorylation of Mig6 on Y394 in vitro, and suppression of Src activity pharmacologically or by shRNA decreased phosphorylation of Mig6 on this site in cells, thus impairing EGFR binding and inhibition. We did not observe a marked difference in the potency of inhibition of EGFR by doubly phosphorylated Mig6 as compared with the singly Y394-phosphorylated protein; thus, the role of priming by Src may be limited to its effect on EGFR-mediated phosphorylation of Y394. Priming may serve to accelerate the time course and/or efficiency of Mig6 inhibition of EGFR when Src is also active. We do not exclude the possibility that other kinases in addition to Src could also contribute to priming. One candidate is c-Abl, which can bind to Mig6 and phosphorylate the Y394-Y395 site 47 .
Deletions involving the 1p36 locus have been noted in a wide variety of human malignancies, hence prompting efforts to identify one or more tumor-suppressive genes in this region 48 . Our analysis points to ERRFI1 as the most significantly deleted 1p gene in the gliomas we studied. We found focal deletions of ERRFI1 in approximately one-fifth of the glioblastomas analyzed. ERRFI1 loss was most often hemizygous. Because Mig6 inhibits EGFR on a strict per-molecule basis, decreased ERRFI1 gene dosage and the consequent lower levels of Mig6 expression could be expected to confer a growth advantage in the context of an EGFR-driven tumor, particularly in the face of high levels of EGFR expression resulting from increased EGFR copy number. Interestingly, ERRFI1 deletions are highly correlated with coexisting EGFR amplification. Co-occurrence of mutations or npg a r t i c l e s copy-number alterations in two genes in the same signaling pathway is atypical; such alterations are usually mutually exclusive, owing to the ability of a single lesion to activate the relevant oncogenic pathway. However, loss of one or both copies of ERRFI1 could be expected to have little effect in the absence of EGFR-pathway activation, because Mig6 requires phosphorylation by active EGFR to be able to inhibit and drive degradation of EGFR. The lung cancer-associated EGFR mutants that we studied here are clearly still sensitive to Mig6 inhibition biochemically and in cells, and the Mig6 Y394-Y395 site is phosphorylated in EGFR-mutant PC9 and HCC827 cells (Fig. 1c) . These findings raise the question of how mutant or amplified EGFR escapes effective inhibition by Mig6. One possible mechanism is substoichiometric expression of Mig6 relative to EGFR. Concordantly with this, we found that overexpression of Mig6 blocks the ability of mutant EGFR to transform NIH-3T3 cells (Fig. 3) . Structural differences in the mutant EGFR asymmetric dimer may also contribute to escape. Because the mutations promote the active conformation of the kinase, both subunits in the mutant dimer may contribute to EGFR signaling, whereas only the 'receiver' subunit is active in ligand-stimulated WT EGFR. Thus, full inhibition of mutant EGFR may require a 2:2 stoichiometry of Mig6 to EGFR, compared with a 1:2 stoichiometry in WT EGFR (Fig. 7b) . In addition, the asymmetric dimer contact is likely to impede the access of Mig6 to the subunit in the activator position 18, 49, 50 . Although the isolated segment 2 interaction is of relatively low affinity, the structure that we describe here may facilitate design of higher-affinity cyclic peptide or peptidomimetic inhibitors that target the peptide substrate-binding site. Such an inhibitor, e.g., Mig6 itself, could be expected to potently inhibit diverse oncogenic EGFR variants, including those that do not respond to available EGFR tyrosine kinase inhibitors.
METHODS
Methods and any associated references are available in the online version of the paper. 
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shRNA studies. Vectors with shRNA targeting c-Src and GFP were purchased from Sigma, and viruses were produced with protocols from the RNAi Consortium (http://www.broadinstitute.org/rnai/trc/). Target cells were plated the day before infection and subsequently incubated with diluted virus in 8 µg/mL polybrene for 6 h. Virus-infected cells were pooled and treated with puromycin for 1 week before experiments were conducted.
Enzyme kinetics. For in vitro enzyme kinetic and inhibition studies, WT or mutant EGFR kinases (residues 696-1022 of human EGFR) were expressed and purified as GST-fusion proteins in Sf9 insect cells, with a protocol essentially as previously described 55 . Kinetic parameters were determined with the ATP/ NADH coupled assay system in a 96-well plates, as previously described 55 Semisynthetic Mig6 phosphoproteins. GST-Mig6 (330389) was cloned into pTXB1 vector (New England BioLabs) and transformed into Escherichia coli BL21(DE3). Transformed cells were cultured at 37 °C until the A 600 reached 0.8 and then were induced with 500 µM IPTG to overexpress the GST-Mig6 (330-389)-intein-CBD fusion protein. Cell pellets were resuspended in 1× PBS with 5% glycerol and 1 mM TCEP, and one tablet of protease inhibitor cocktail (Roche), and lysed by sonication. After centrifugation at 17,000 r.p.m. for 40 min to remove cell debris, the supernatant was collected, incubated with GST-Sepharose (GE Healthcare) beads for affinity purification and then eluted with 10 mM glutathione. Eluted protein was treated with TEV protease for 6 h to remove the GST-fusion partner and then loaded onto chitin beads (New England BioLabs) for affinity purification and ligation with peptide. The chitin beadbound fusion protein was washed with washing buffer (500 mM NaCl, 50 mM HEPES, pH 7.4, and 1 mM TCEP) and then equilibrated in cleavage buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, and 0.1 mM TCEP). Addition of 200 mM 2-mercaptoethane sulfonate (MESNA, Sigma-Aldrich) in cleavage buffer at 4 °C for 12 h induced release of the Mig6 thioester. To obtain the desired semisynthetic phosphoproteins, 1 mM of synthetic Mig6 phosphopeptide (CSTHpYYLLPE, CSTHYpYLLPE, or CSTHpYpYLLPE) was added to the cleaved Mig6 thioester solution. The ligation reaction was allowed to proceed for 48 h at 4 °C. The ligated phospho-Mig6 proteins were purified with cation-exchange chromatography (Mono S) and size-exclusion chromatography (Superdex 75). The unphosphorylated Mig6 (330-399) was obtained by E. coli expression and purified with the same conditions used for the semisynthetic Mig6 phosphoproteins. The correct masses and the phosphorylation state of each of the Mig6 proteins were verified by mass spectrometry.
Structure determination. The L858R-mutant EGFR kinase domain was crystallized as previously described 55 . Synthetic phosphopeptides based on the Mig6 Y394 and Y395 phosphorylation sites (with sequences SSTHYpYLLPE and SSTHpYpYLLPE) were soaked into the apocrystals in reservoir solution supplemented with 1 mM peptide for 5 h. For cocrystallization of WT EGFR with segment 1+2 phospho-Mig6 (330-399), the protein complex was prepared by size-exclusion chromatography with (Superdex 200, GE Healthcare) and concentrated to 2.5 mg/ml. Crystals were obtained by hanging-drop vapor diffusion against 25% polyethylene glycol 3350, 200 mM ammonium acetate and 100 mM Bis-Tris, pH 5.5. All diffraction data were collected with a wavelength of 0.979 Å on the NE-CAT beamlines ID24-C and E, Argonne National Laboratory, at 100 K and were processed and merged with HKL2000 (ref. 56) . The peptidecomplex structures were determined by molecular replacement with the EGFR L858R kinase structure as a search model (PDB 2ITV). L858R-mutant EGFR was used in this study, but the mutation does not appear to affect interactions with Mig6. The Mig6 segment 1+2 complex structure was determined by molecular replacement with the structure of EGFR in complex with Mig6 segment 1 as a search model (PDB 2RF9). This structure contains two closely similar EGFR-Mig6 complexes in the crystallographic asymmetric unit (r.m.s. deviation 0.39); molecule A is described and illustrated here. For all structures, the Mig6 sequences were modeled into closely fitting positive F o − F c density, and repeated rounds of manual refitting and crystallographic refinement were performed with COOT 57 and PHENIX 58 . Crystallographic data collection and refinement statistics are presented in Table 1 .
Size-exclusion chromatography with EGFR-Mig6 complex. The EGFR L858R kinase (residues 696-1022) was combined with a two-fold molar excess of unphosphorylated Mig6 (residues 330-399) and incubated at room temperature with 1 mM ATP in reaction buffer (0.1 M HEPES, pH 7.5, 0.1 M NaCl, 2 mM TCEP, and 2 mM MnCl 2 ). After a 20-min incubation, 20 mM EDTA was added to quench the reaction, and the reaction mixture was subjected to size-exclusion chromatography (Superose 200). Eluted fractions were analyzed by SDS-PAGE and immunoblotting with anti-pMig6 (pY394pY395).
Off-rate determination. A two-fold molar excess of EGFR L858R kinase (residues 696-1022) was combined with unphosphorylated GST-Mig6 (residues 330-399) in reaction buffer (0.1 M HEPES, pH 7.5, 0.1 M NaCl, 2 mM TCEP, and 2 mM MnCl 2 ) with or without 10 mM ATP. After 20-min incubation at room temperature, identical aliquots of the reaction mixture were loaded onto GST-Sepharose beads in spin columns and vigorously washed with reaction buffer. Beads in each spin column were maintained under flow with reaction buffer for the indicated time periods and then eluted with 10 mM glutathione in reaction buffer. Eluted samples were analyzed by SDS-PAGE, and the molar ratio of EGFR and Mig6 proteins was quantified by densitometry (ImageQuant, GE Healthcare).
Genomic analyses. Copy-number data from TCGA (refs. 21,59) were analyzed as described 46 to identify recurrent alterations and correlated and anticorrelated events. Genome-wide results of the recurrence analyses are available at http:// www.broadinstitute.org/tcga/ under the 2014-07-08 stddata_2014_06_14 analysis version. Clustering of copy-number profiles was performed with Ward's method as implemented in R and a Euclidean distance metric on a matrix of 10-kb bins across chromosome 1p. Samples were called as having EGFR focal amplifications or ERRFI1 focal deletions if they exhibited focal copy-number alterations surpassing 0.1 and −0.1 copies in amplitude, respectively. Mutation calls for FUBP1 were taken from TCGA analyses 21, 59 .
